You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The goal of the project is to build a liquid biopsy-based early detection technology platform and develop tests for lung and digestive system cancers.
The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.
If validation testing goes to plan, the firm believes it can have an inexpensive coronavirus test available for use at the point of care in about six months.
The test was selected for accelerated development and commercialization support by the NIH through the RADx Tech program for COVID-19 diagnostics.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
The developer said that use of gold nanoparticles enables use at the point of care and inexpensive signal amplification that eliminates traditional equipment.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.